

# Guided versus standard antiplatelet therapy in patients undergoing interventional intracranial aneurysm treatment using stents: protocol of a cluster randomized controlled cohort study

1 Yangyang Zhou<sup>1</sup>, Wenqiang Li<sup>1</sup>, Hongqi Zhang<sup>2</sup>, Bin Luo<sup>3</sup>, Yang Wang<sup>4</sup>, Jun  
2 Wang<sup>5</sup>, Pinyuan Zhang<sup>6</sup>, Liang Li<sup>7</sup>, Fushun Xiao<sup>8</sup>, Shiqing Mu<sup>1</sup>, Jian Liu<sup>1</sup>,  
3 Yuanli Zhao<sup>1</sup>, Xinjian Yang<sup>1\*</sup>, Peng Jiang<sup>1\*</sup>

4

5 \*Correspondence:

6 Dr. Peng Jiang E-mail: [jiangpeng33@126.com](mailto:jiangpeng33@126.com)

7 Address: Department of Interventional Neuroradiology, Beijing Neurosurgical  
8 Institute and Beijing Tiantan Hospital, Capital Medical University, Beijing 100070,  
9 China.

10 Dr. Xinjian Yang

11 E-mail: [yangxinjian@voiceoftiantan.org](mailto:yangxinjian@voiceoftiantan.org)

12 Address: Department of Interventional Neuroradiology, Beijing Neurosurgical  
13 Institute and Beijing Tiantan Hospital, Capital Medical University, Beijing, China.

14

15 **Xinjian Yang and Peng Jiang share corresponding authorship**

16

17 <sup>1</sup>Department of Interventional Neuroradiology, Beijing Neurosurgical Institute and  
18 Beijing Tiantan Hospital, Capital Medical University, Beijing, China.

19 <sup>2</sup>Department of Neurosurgery, Beijing Xuanwu Hospital, Capital Medical University,  
20 Beijing, China.

21 <sup>3</sup>Department of Neurosurgery, Peking University International Hospital, Beijing,  
22 China

23 <sup>4</sup>Department of Neurosurgery, Beijing Chaoyang Hospital, Capital Medical  
24 University, Beijing, China.

25 <sup>5</sup>Department of Neurology, The Chinese PLA General Hospital, Beijing, China

26 <sup>6</sup>Department of Neurosurgery, The Third Hospital of Hebei Medical University,  
27 Shijiazhuang, China.

28 <sup>7</sup>Department of Neurosurgery, Peking University First Hospital, Beijing, China.

29 <sup>8</sup>Department of Neurosurgery, Tianjin Medical University General Hospital, Tianjin,  
30 China.

31

32

33 **Disclaimers:** The findings and conclusions in this report are those of the author(s).

34

35 **Funding:** This study was sponsored by the National Natural Science Foundation of China (grant  
36 numbers: 81671139, 82072036, 82372058 and 82371315), Capital's Funds for Health

37 **NOTE:** This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. Improvement and Research (grant numbers: 2022-1-2041) and Summit Talent Program (grant

1 numbers: DFL20220504).

2

3 *Disclosure of relationships and activities: The authors declare that the research was*  
4 *conducted in the absence of any commercial or financial relationships that could be*  
5 *construed as a potential conflict of interest.*

6

7 **Ethics and dissemination** This study involves human participants and was approved  
8 by the Ethics Committee of Beijing Tiantan Hospital (KY2022-068-02). Participants  
9 gave informed consent to participate in the study before taking part.

10

11 **Trial registration number** NCT05825391.

12

13

1 **ABSTRACT**

2 **Background** The goal of standard dual antiplatelet therapy (SDAT) in patients  
3 undergoing endovascular interventional treatment of intracranial aneurysms is to  
4 prevent thrombosis; however, some patients have a poor response to these drugs,  
5 which increases the risk of cerebral infarction. This study aims to examine whether  
6 adjusting antiplatelet therapy based on light transmission aggregometry (LTA) can  
7 reduce the incidence of ischemic events compared with SDAT.

8 **Methods** We will conduct a cluster randomized controlled trial using 16 treatment  
9 teams from eight hospitals in mainland China, enrolling 590 patients with unruptured  
10 intracranial aneurysms treated using endovascular stent placement. The treatment  
11 teams serving as clusters will be randomly assigned to either the test or control group  
12 at a 1:1 ratio. Test group patients will receive an antiplatelet regimen guided by LTA.  
13 Control group patients will receive SDAT. Patients will be followed for 1 month after  
14 the treatment period. The primary outcome measure is cerebral ischemic events within  
15 30 days of stent placement, including stent thrombosis, ischemic stroke, and transient  
16 ischemic attack. The safety measure is all bleeding events within 30 days of treatment.

17 **Discussion** The trial aims to determine whether LTA-guided antiplatelet therapy  
18 reduces the incidence of ischemic events without increasing the risk of bleeding in  
19 patients with intracranial aneurysms treated with endovascular stenting. Completion  
20 of this clinical trial may provide an individualized safe and effective regimen for  
21 antiplatelet therapy.

22 **Trial registration** [ClinicalTrials.gov](https://clinicaltrials.gov), NCT05825391. Registered on April 11, 2023.

1 **What is already known on this topic**

2 Dual antiplatelet therapy is administered to reduce thrombotic events in  
3 neurointerventional therapy of intracranial aneurysms. Platelet function testing is used  
4 to evaluate the antiplatelet effect of aspirin and clopidogrel.

5 **What this study adds**

6 The trial aims to determine whether LTA-guided antiplatelet therapy reduces the  
7 incidence of ischemic events without increasing the risk of bleeding in patients with  
8 intracranial aneurysms treated with endovascular stenting.

9 **How this study might affect research, practice or policy**

10 For stent neurointerventional therapy of unruptured intracranial aneurysms, this study  
11 could provide a promising method for adjusting appropriate antiplatelet therapy.

12

## 1 **Background**

2 Intracranial aneurysms are generally treated using endovascular interventional therapy  
3 when possible.<sup>1,2</sup> The use of intracranial endovascular stents, particularly flow  
4 diverters, has greatly expanded the indications for interventional therapy and has  
5 contributed to improved treatment success rates. However, the presence of an  
6 endovascular stent also increases the risk of ischemic complications.<sup>3,4</sup> Standard dual  
7 antiplatelet therapy (SDAT), which consists of oral aspirin 100 mg and clopidogrel 75  
8 mg daily, is administered to stent patients to reduce the incidence of thrombotic events.  
9 However, the response to antiplatelet agents varies between patients. Some patients  
10 respond poorly, particularly to clopidogrel, and the incidence of thrombotic events can  
11 reach 40%.<sup>5</sup>

12 Platelet function testing is important to identify patients with antiplatelet drug  
13 resistance. Intensifying antiplatelet therapy in such patients may help reduce the risk  
14 of ischemic complications.<sup>6,7</sup> Light transmittance aggregometry (LTA) is the gold  
15 standard for detecting platelet aggregation function, which may have importance in  
16 patients undergoing interventional intracranial aneurysm treatment.<sup>8</sup> Maximum  
17 platelet aggregation rate induced by adenosine diphosphate (ADP) can be used to  
18 predict ischemic events using previously established cut-off values.<sup>9</sup>

19 Ticagrelor is a reversible P2Y<sub>12</sub> receptor antagonist with rapid onset. Unlike  
20 clopidogrel, it does not require CYP450 enzymatic metabolism for activity and its  
21 efficacy is not affected by CYP2C19 gene polymorphisms.<sup>10</sup> Therefore, we will  
22 conduct a cluster randomized controlled cohort study to examine whether LTA-guided

1 antiplatelet therapy reduces the incidence of ischemic complications in patients  
2 undergoing endovascular intervention for intracranial aneurysm treatment.

3

#### 4 **Methods**

##### 5 **Study design and objectives**

6 This is a prospective multicenter cluster randomized controlled study evaluating the  
7 efficacy and safety of LTA-guided antiplatelet therapy in patients with unruptured  
8 intracranial aneurysms undergoing endovascular stenting. Sixteen neurointerventional  
9 treatment teams from eight hospitals will be involved. Treatment team inclusion  
10 criteria are shown in **Box 1**. The 16 teams will be randomly divided into test and  
11 control groups at a 1:1 ratio. Test group patients will receive an antiplatelet regimen  
12 guided by LTA testing and control group patients will receive SDAT. The primary  
13 outcome measure will be incidence of ischemic events 30 days after treatment, which  
14 will be compared between the test and control groups (**Fig. 1**).

15

1

<b>Box 1. Neurointerventional treatment team inclusion criteria</b>
---

- |  |
|--|
| <ol style="list-style-type: none"><li>1. The team is located in a hospital which can independently perform endovascular interventional therapy for intracranial aneurysms.</li><li>2. Attending interventionists of the team have more than 10 years of experience in aneurysm treatment.</li><li>3. The team performs more than 10 interventional procedures per month for unruptured aneurysms on average.</li></ol> |
|--|

2

3 **Study population**

4 Patient inclusion and exclusion criteria are shown in **Box 2**. The study will enroll 590  
5 patients with unruptured intracranial aneurysms.

6

1

## **Box 2. Patient inclusion and exclusion criteria**

### **Inclusion criteria**

1. Patients undergoing intracranial stenting for an unruptured intracranial aneurysm.
2. Standard dual antiplatelet therapy at least 5 days before stenting.
3. Age 18 to 80 years.
4. Modified Rankin scale <2 on the day of enrollment.
5. Provision of written informed consent.

### **Exclusion criteria**

1. Patients with a recurrent aneurysm after interventional treatment or surgical clipping.
2. Allergy to aspirin, clopidogrel, or ticagrelor.
3. Prophylactic use of other antiplatelet drugs (tirofiban, for example) before stent placement.
4. High probability of active bleeding owing to a symptomatic intracranial hemorrhage or active gastric ulcer or history of bleeding or coagulation disorder.
5. Abnormal platelet count (normal range,  $100\text{--}300 \times 10^9/\text{L}$ ).
6. Patients on an anticoagulant medication.
7. Pregnant or lactating women.
8. Patients with liver disease, kidney disease, congestive heart failure, or malignancy.

2

3



1 **Measures and observation variables**

2 We will collect the following data: 1) demographic characteristics—age, gender,  
3 height, weight, body mass index; 2) past medical history—hypertension, diabetes,  
4 coronary heart disease, hyperlipidemia, medications (type, dose, frequency), smoking  
5 and drinking history, family history, surgical history; 3) laboratory testing data—  
6 complete blood count, liver function, kidney function, blood glucose, blood lipids,  
7 coagulation parameters, LTA; 4) physical examination—neurological examination,  
8 modified Rankin scale score; 5) aneurysm characteristics—size, number, location,  
9 shape, neck width, diameter of parent artery.

10

11 **Randomization**

12 Random numbers will be generated by an independent third-party using SPSS  
13 software version 26.0 (IBM Corp., Armonk, NY, USA) to generate a random  
14 sequence. Eight treatment teams will be randomly assigned to the test group and eight  
15 to the control group. The results of randomization will be made clear to the  
16 participating investigators and patients.

17

18 **Guarantee of independence of test and control groups.**

19 After randomization is completed, the treatment teams will strictly adhere to the  
20 assigned test or control protocol. In hospitals with treatment teams in both groups,  
21 patients in the treatment and control groups will be admitted to different wards to  
22 ensure no interference between them. An appointed hospital research supervisor will

1 oversee protocol operations to ensure group independence.

2

### 3 **LTA testing**

4 To ensure consistency and quality across different research centers, this study utilized  
5 an automatic platelet aggregator from the same manufacturer (AG800, Techlink  
6 Biomedical Technology Co., Ltd., Beijing, China). In each treatment team of test  
7 group, an automatic platelet aggregator was placed in the ward. Prior to the start of  
8 the study, the instrument was uniformly calibrated and debugged, using quality  
9 control products provided by the manufacturer for detection. Additionally, all  
10 participants underwent intensive training before being allowed to work on the sample  
11 collection and analysis process. This training included theoretical learning and the  
12 acquisition of operation skills, ensuring the standardization of the process.

13 The experimental conditions for the inspection process were standardized as follows:

14 (1) Specimen collection: After puncture, collect two 3ml tubes of fasting venous  
15 whole blood into citrate anticoagulated plastic vacuum blood collection tubes. (2)  
16 Plastic blood collection tubes were used for blood collection, and the plug containing  
17 magnesium ion was not used. (3) If the red blood cell specific volume (HCT) was  
18 greater than 55% during blood collection, the amount of anticoagulant was adjusted.  
19 (4) After blood collection (20~25 °C), the test was completed within 4 hours after  
20 storage, and the specimen was not vibrated during transportation. (5) All samples  
21 were collected between 8:00-10:00 a.m. and detected by computer within 4 hours  
22 after collection. (6) The platelet count of collected samples was greater than  $100 \times$

1 109/L. (7) Centrifugation conditions for rich and poor plasma: platelet-rich plasma  
2 was centrifuged at 160 g / 10 min, and platelet-poor plasma was centrifuged at 2000 g  
3 / 10 min. (8) Inducer standards used: final concentration of ADP was 5  $\mu\text{mol} / \text{L}$ , and  
4 the final concentration of arachidonic acid (AA) was 0.25 mg / ml. (9) Inducer storage  
5 conditions: after the powder dissolves into liquid, it can be stored at -20 °C for 1  
6 month, and at 2~8 °C for 1 week. (10) Instruments and consumables used: disposable  
7 cuvette (inner circle without dead angle and light transmittance), disposable mixing  
8 rod with two semicircular ends without acute angles, fixed stirring speed of 850 rpm,  
9 and a light source wavelength of 575 nm.

10

## 11 **Antiplatelet therapy and interventions**

12 Prior to endovascular treatment, all patients will receive SDAT for at least 5 days.  
13 Patients in the test group will receive a guided antiplatelet regimen based on LTA  
14 testing; those with unsatisfactory platelet aggregation rates will undergo appropriate  
15 regimen adjustments (**Fig 2**). Test group patients will undergo drug adjustment at least  
16 24 hours before stent implantation. LTA testing will be re-checked 48 hours after any  
17 drug regimen adjustment. All procedures will be performed under general anesthesia.  
18 Activated clotting time will be used to guide heparin administration during the  
19 procedure, with a target of 250 to 300 seconds. Typical dosing will be a 3000 to 5000  
20 unit bolus at the start of the procedure and then 1000 units per hour. Stent selection  
21 will be based on anatomical measurements of the aneurysm and parent artery. After  
22 the procedure, patients will continue to take the same dual antiplatelet drugs as before.

1 Those who undergo placement of traditional stents will take clopidogrel or ticagrelor  
2 for at least 6 weeks and aspirin for at least 6 months. Patients who undergo flow  
3 diverter placement will take clopidogrel or ticagrelor for at least 3 months and aspirin  
4 for life.

5

## 6 **Outcome measures**

7 The primary outcome measure is ischemic events within the first 30 days after the  
8 procedure, including stent thrombosis, ischemic stroke, or transient ischemic attack.

9 Stent thrombosis is defined as thrombosis at the stent site confirmed by digital  
10 subtraction angiography after stent implantation. Ischemic stroke is defined as rapid  
11 onset of a new focal neurological deficit with clinical or radiographic evidence of  
12 infarction, or rapid deterioration of an existing focal neurological deficit owing to a  
13 new infarction.<sup>11</sup> Transient ischemic attack is defined as transient neurological  
14 dysfunction caused by focal cerebral ischemia.<sup>12</sup>

15 Exploratory outcome measures are ischemic events within the first 7 days of the  
16 procedure, modified Rankin scale score 30 days after the procedure and death from  
17 any cause.

18 The safety outcome is all bleeding events within 30 days of the procedure. Bleeding  
19 events will be graded according to the GUSTO grading criteria: 1) severe or life-  
20 threatening bleeding—intracranial bleeding or hemodynamically impaired bleeding  
21 requiring intervention; 2) moderate bleeding—bleeding requiring blood transfusion  
22 but not causing hemodynamic impairment; 3) minor bleeding—bleeding that does not

1 meet the criteria for severe or moderate bleeding.<sup>13</sup> Intracranial hemorrhage will be  
2 diagnosed using computed tomography or magnetic resonance imaging. Other types  
3 of hemorrhage will be diagnosed based on symptoms and imaging.

4 Study visits will be conducted on days 1, 3, 7, and 30 after the procedure to evaluate  
5 neurological status, ischemic events, and bleeding events. A five-member study  
6 committee will be formed to ensure safety and data reliability: a two-member data  
7 safety monitoring committee and three-member clinical event review committee. All  
8 ischemic and bleeding events will be assessed independently by each member of the  
9 clinical event committee. Committee members will be blinded to treatment group  
10 assignments. Any disagreements or discrepancies will be resolved via consensus.

11

## 12 **Subgroup analysis**

13 The study will also assess whether guided antiplatelet therapy yields distinct  
14 therapeutic outcomes in various subgroups. Subgroup analyses will include a  
15 comparison between patients treated using flow diversion and those treated using  
16 traditional stent-assisted coil embolization, as well as stratified analyses based on  
17 factors such as age, sex, body mass index, smoking status, operation time, previous  
18 ischemic stroke, and the presence of combined atherosclerotic lesions.

19

## 20 **Sample size and data analysis1**

21 In a previous randomized controlled study of patients undergoing stent placement for  
22 intracranial aneurysm treatment, the incidence of ischemic events within 30 days of

1 treatment in patients who received antiplatelet drug adjustment based on platelet  
2 function testing and those who received conventional treatment without monitoring  
3 was 5.1% and 12.1%, respectively.<sup>14</sup> Based on a previous study, the intracluster  
4 correlation coefficient is assumed to be 0.002 in this study.<sup>15</sup> With a test level of 0.05  
5 and a power of 0.8, we anticipate recruiting 35 patients from each cluster (treatment  
6 team). Therefore, a total of 560 patients are required. Assuming a 5% attrition rate,  
7 590 patients will be recruited (295 patients in the test and control groups,  
8 respectively). Each group will have one treatment team that recruits 36 patients; the  
9 other teams will recruit 37.

10 All analyses will be performed on the individual level with adjustment for clustering.  
11 All available data from the dropouts will be included in the analysis up to the time of  
12 dropout when possible. Statistical hypothesis tests will be two-tailed and performed at  
13 a 5% significance level. Continuous data will be tested for normality using the  
14 Shapiro–Wilk test. Normally distributed data will be expressed as means with  
15 standard deviation; skewed data will be expressed as medians with interquartile range.  
16 Categorical data will be expressed as numbers with percentage. Cluster-adjusted  
17 baseline differences between the two groups will be analyzed using the independent  
18 Student’s t test or Mann–Whitney U test for continuous variables and the Pearson  $\chi^2$   
19 test for categorical variables. All outcome event analyzes will be analyzed using  
20 generalized linear mixed-effects models with intervention as the fixed effect and the  
21 treatment team as the random effect to account for potential correlations in outcomes  
22 within each treatment team. Any variables that are unbalanced between the test and

1 control groups ( $P < 0.1$ ) will be introduced into the model to adjust for confounders.

2

### 3 **Data collection and management**

4 Researchers will enter data into the electronic data capture system in a timely fashion.

5 All content required by the study plan in the system will be provided. Unfilled content

6 will be explained. All outcomes arising during the study will be reported to the

7 steering committee, which will review the reported events to ensure they meet the

8 outcome definitions. Imaging data from computed tomography, magnetic resonance

9 imaging, and digital subtraction angiography will be collected in DICOM format.

10 Laboratory examination data will be collected by uploading photos. Imaging data will

11 be sent to the designated data management center by the research inspector. The

12 person in charge of the data management center will check and sign for receipt. All

13 study files will be kept at all participating testing centers for at least 10 years. After

14 study completion, the data will be reviewed by the research ethics committee, quality

15 assurance committee, and other regulatory bodies. Study documentation in paper form

16 (consent forms, questionnaires, and source datasets from the chart coordinator) will be

17 securely stored. All computerized files will be password protected.

18

## 1 **DISCUSSION**

2 In the neurointerventional treatment of intracranial aneurysms, SDAT is routinely  
3 administered to prevent thrombosis. However, the value of platelet function testing in  
4 patients receiving these drugs is controversial.<sup>5,16-18</sup> A randomized controlled trial of  
5 coil embolization of unruptured cerebral aneurysms showed that modified antiplatelet  
6 therapy based on VerifyNow P2Y12 testing, which is commonly used because of its  
7 convenience, can reduce thromboembolic complications.<sup>19</sup> However, LTA is the gold  
8 standard of platelet function testing and its value in patients undergoing endovascular  
9 interventional treatment of intracranial aneurysms has not yet been established. A  
10 single-center randomized controlled study confirmed that LTA-guided antiplatelet  
11 therapy in patients receiving ticagrelor helped reduce postoperative ischemic events;  
12 however, overall bleeding events significantly increased.<sup>14</sup> Another study calculated  
13 optimal cut-off values for predicting ischemic events in patients who received  
14 traditional stents and flow diverters, which were 42.9% and 36.4% of the maximum  
15 platelet aggregation rates, respectively.<sup>9</sup>

16 Based on the above studies, we will conduct a multicenter prospective cluster  
17 randomized controlled study and adjust antiplatelet drugs according to the maximum  
18 platelet aggregation rate cut-offs. We hypothesize that LTA-guided antiplatelet therapy  
19 will reduce the incidence of ischemic events without increasing the incidence of major  
20 bleeding events compared with SDAT. The advantages of this study lie in the  
21 following aspects: multicenter design, standardized LTA testing across participating  
22 centers, customized cutoff values and antiplatelet regimens for flow diversion, and the  
23 use of low-dose ticagrelor. The results may provide evidence of a safe and effective



1 alternative antiplatelet therapy for patients with intracranial aneurysms undergoing  
2 stent placement.

3 The study uses a cluster-randomized controlled design at the treatment team level in  
4 which the teams, not subjects, are randomized to avoid contamination of subjects in  
5 the same ward. Each treatment team only provides one type of treatment (test or  
6 control), which streamlines researcher training, alleviates the dilemma of physicians  
7 having to take both clinical treatment and research implementation into account, and  
8 avoids confusion.

9 We recognize the potential limitations of the trial. First, since the study will include  
10 only Asian patients, the results may not be applicable to other populations. Second, it  
11 focuses only on patients undergoing endovascular stenting for treatment of unruptured  
12 aneurysms. Therefore, the results will not apply to patients with ruptured aneurysms  
13 or those undergoing other stenting procedures. Third, because the study will be  
14 conducted in multiple centers, the LTA test results may be heterogeneous despite our  
15 best efforts to use the same testing equipment and uniform training protocols.

16

17

18

## 1     **References**

- 2     1.     Molyneux AJ, Kerr RS, Yu LM, et al. International subarachnoid aneurysm trial (ISAT) of  
3     neurosurgical clipping versus endovascular coiling in 2143 patients with ruptured  
4     intracranial aneurysms: a randomised comparison of effects on survival, dependency,  
5     seizures, rebleeding, subgroups, and aneurysm occlusion. *Lancet*. 2005;366(9488):809-  
6     817.
- 7     2.     Molyneux AJ, Kerr RS, Birks J, et al. Risk of recurrent subarachnoid haemorrhage, death,  
8     or dependence and standardised mortality ratios after clipping or coiling of an  
9     intracranial aneurysm in the International Subarachnoid Aneurysm Trial (ISAT): long-  
10    term follow-up. *Lancet Neurol*. 2009;8(5):427-433.
- 11    3.     Ryu CW, Park S, Shin HS, Koh JS. Complications in Stent-Assisted Endovascular Therapy  
12    of Ruptured Intracranial Aneurysms and Relevance to Antiplatelet Administration: A  
13    Systematic Review. *AJNR Am J Neuroradiol*. 2015;36(9):1682-1688.
- 14    4.     Walcott BP, Stapleton CJ, Choudhri O, Patel AB. Flow Diversion for the Treatment of  
15    Intracranial Aneurysms. *JAMA Neurol*. 2016;73(8):1002-1008.
- 16    5.     Delgado Almandoz JE, Kadkhodayan Y, Crandall BM, Scholz JM, Fease JL, Tubman DE.  
17    Variability in initial response to standard clopidogrel therapy, delayed conversion to  
18    clopidogrel hyper-response, and associated thromboembolic and hemorrhagic  
19    complications in patients undergoing endovascular treatment of unruptured cerebral  
20    aneurysms. *J Neurointerv Surg*. 2014;6(10):767-773.
- 21    6.     Nakagawa I, Park HS, Kotsugi M, et al. Active management of the target P2Y12 reaction  
22    unit range in patients undergoing stent-assisted coil embolization for unruptured  
23    cerebral aneurysms. *J Neurointerv Surg*. 2021;13(11):1017-1021.
- 24    7.     Kim YD, Kwon OK, Ban SP, et al. The inhibition rate estimated using VerifyNow can help  
25    to predict the thromboembolic risk of coil embolization for unruptured intracranial  
26    aneurysms. *J Neurointerv Surg*. 2022;14(6):589-592.
- 27    8.     Adeeb N, Griessenauer CJ, Shallwani H, et al. Pipeline Embolization Device in Treatment  
28    of 50 Unruptured Large and Giant Aneurysms. *World Neurosurg*. 2017;105:232-237.
- 29    9.     Zhou Y, Li W, Wang C, et al. Roles of light transmission aggregometry and CYP2C19  
30    genotype in predicting ischaemic complications during interventional therapy for  
31    intracranial aneurysms. *Stroke Vasc Neurol*. 2023.
- 32    10.    Wang Y, Meng X, Wang A, et al. Ticagrelor versus Clopidogrel in CYP2C19 Loss-of-  
33    Function Carriers with Stroke or TIA. *N Engl J Med*. 2021;385(27):2520-2530.
- 34    11.    Sacco RL, Kasner SE, Broderick JP, et al. An updated definition of stroke for the 21st  
35    century: a statement for healthcare professionals from the American Heart  
36    Association/American Stroke Association. *Stroke*. 2013;44(7):2064-2089.
- 37    12.    Easton JD, Saver JL, Albers GW, et al. Definition and evaluation of transient ischemic  
38    attack: a scientific statement for healthcare professionals from the American Heart  
39    Association/American Stroke Association Stroke Council; Council on Cardiovascular  
40    Surgery and Anesthesia; Council on Cardiovascular Radiology and Intervention; Council  
41    on Cardiovascular Nursing; and the Interdisciplinary Council on Peripheral Vascular  
42    Disease. The American Academy of Neurology affirms the value of this statement as an  
43    educational tool for neurologists. *Stroke*. 2009;40(6):2276-2293.

- 1 13. investigators G. An international randomized trial comparing four thrombolytic  
2 strategies for acute myocardial infarction. *N Engl J Med.* 1993;329(10):673-682.
- 3 14. Li W, Zhu W, Wang A, et al. Effect of Adjusted Antiplatelet Therapy on Preventing  
4 Ischemic Events After Stenting for Intracranial Aneurysms. *Stroke.* 2021;52(12):3815-  
5 3825.
- 6 15. Gulliford MC, Adams G, Ukoumunne OC, Latinovic R, Chinn S, Campbell MJ. Intra-class  
7 correlation coefficient and outcome prevalence are associated in clustered binary data. *J*  
8 *Clin Epidemiol.* 2005;58(3):246-251.
- 9 16. Kim YD, Kwon OK, Ban SP, et al. The inhibition rate estimated using VerifyNow can help  
10 to predict the thromboembolic risk of coil embolization for unruptured intracranial  
11 aneurysms. *J Neurointerv Surg.* 2021.
- 12 17. Miller TR, Wessell A, Jindal G, Malhotra A, Simard JM, Gandhi D. The utility of platelet  
13 inhibition testing in patients undergoing Pipeline embolization of intracranial aneurysms.  
14 *J Neurointerv Surg.* 2022;14(1).
- 15 18. Kim KS, Fraser JF, Grupke S, Cook AM. Management of antiplatelet therapy in patients  
16 undergoing neuroendovascular procedures. *J Neurosurg.* 2018;129(4):890-905.
- 17 19. Hwang G, Huh W, Lee JS, et al. Standard vs Modified Antiplatelet Preparation for  
18 Preventing Thromboembolic Events in Patients With High On-Treatment Platelet  
19 Reactivity Undergoing Coil Embolization for an Unruptured Intracranial Aneurysm: A  
20 Randomized Clinical Trial. *JAMA Neurol.* 2015;72(7):764-772.
- 21
- 22

1 **Figures and legends**


2


3 Figure 1. Study flow chart. LTA, light transmittance aggregometry.

4

5 Figure 2. Light transmission aggregometry-guided antiplatelet therapy in the test  
6 group. SDAT, standard dual antiplatelet therapy (aspirin 100 mg and clopidogrel 75  
7 mg daily); AA-MPA, maximum platelet aggregation rate induced by arachidonic acid,  
8 ADP-MPA, maximum platelet aggregation rate induced by adenosine diphosphate.

9 \*Aspirin meets the standard:  $0 < \text{AA-MPA} < 20\%$ ; Clopidogrel meets the standard:  $20\%$   
10  $< \text{ADP-MPA} < 36.4\%$  (for flow diverter) or  $20\% < \text{ADP-MPA} < 42.9\%$  (for traditional  
11 stent).





- SDAT, standard dual antiplatelet therapy (aspirin 100mg and clopidogrel 75mg daily); AA-MPA, maximum platelet aggregation rate induced by arachidonic acid, ADP-MPA, maximum platelet aggregation rate induced by adenosine diphosphatase.
- \*Aspirin meets the standard:  $0 < \text{AA-MPA} < 20\%$ ; Clopidogrel meets the standard:  $20\% < \text{ADP-MPA} < 36.4\%$  (for flow diverter ) or  $20\% < \text{ADP-MPA} < 42.9\%$  (for traditional stent).